Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Fulvestrant plus anastrozol bij gemetastaseerd mammacarcinoom: langetermijnresultaten
jun 2019 | Borstkanker